Dario Cattaneo

Emilio Clementi12
Cristina Gervasoni10
Laura Milazzo4
Sara Baldelli4
Serena Fucile3
12Emilio Clementi
10Cristina Gervasoni
4Laura Milazzo
4Sara Baldelli
3Serena Fucile
Learn More
The current therapy for chronic proteinuric nephropathies is angiotensin-converting enzyme inhibitors (ACEi), which slow, but may not halt, the progression of disease, and which may be not effective to the same degree in all patients. In accelerated passive Heymann nephritis (PHN), this study assessed the effect of combining ACEi with angiotensin II(More)
BACKGROUND Improvements of bio-nano-technologies and biomolecular techniques have led to increasing production of high-throughput experimental data. Spotted cDNA microarray is one of the most diffuse technologies, used in single research laboratories and in biotechnology service facilities. Although they are routinely performed, spotted microarray(More)
  • Cristina Gervasoni, Paola Meraviglia, Simona Landonio, Sara Baldelli, Serena Fucile, Laura Castagnoli +5 others
  • 2013
Treatment with tenofovir sometimes leads to non-reversible kidney and/or bone diseases. Factors associated with these drug-related adverse events are poorly characterized. Our objective was to investigate such factors in patients treated long term with daily tenofovir. One-hundred Caucasian HIV-positive patients with basal creatinine clearance >80 mL/min(More)
Available guidelines on therapeutic drug monitoring of second-generation antipsychotics were designed for adults; therefore, they cannot be transferred as such in pediatric patients, who may have different drug absorption, distribution, metabolism, and elimination. Moreover, available tools that guide dosing in neuropsychiatric pediatric patients are scant,(More)
We designed two Phase I studies that assessed healthy volunteers in order to evaluate the safety and to optimize the dosing of the combination of the drugs isosorbide dinitrate, a nitric oxide donor, and ibuprofen, a nonsteroidal antiinflammatory drug. We designed these studies with the aim of designing a Phase II trial to evaluate the drugs' efficacy in(More)
  • Francesca Ferretti, Alba Bigoloni, Laura Passeri, Laura Galli, Valeria Longo, Simonetta Gerevini +9 others
  • 2016
BACKGROUND Cerebrospinal fluid (CSF) viral escape is a concern in ritonavir-boosted protease inhibitors monotherapy. The aim was to assess HIV-RNA, biomarkers of immune activation and neurodegeneration, and atazanavir concentrations in CSF of patients on successful long-term atazanavir/ritonavir (ATV/r) monotherapy. METHODS This is a substudy of the(More)
  • Cristina Gervasoni, Paola Meraviglia, Davide Minisci, Laurenzia Ferraris, Agostino Riva, Simona Landonio +7 others
  • 2015
INTRODUCTION Ritonavir-boosted atazanavir (ATV/r) is a relatively well tolerated antiretroviral drug. However, side effects including hyperbilirubinemia, dyslipidemia, nephrolithiasis and cholelithiasis have been reported in the medium and long term. Unboosted ATV may be selected for some patients because it has fewer gastrointestinal adverse effects, less(More)